Lista de obras -

A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia

artículo científico publicado en 2010

Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase

artículo científico publicado en 2003

Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations

artículo científico publicado en 2018

Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase.

artículo científico publicado en 2007

Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase

artículo científico publicado en 2003

Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapy

artículo científico publicado en 2002

Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance

artículo científico publicado en 2009

Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment

artículo científico publicado en 2017

Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis

artículo científico publicado en 2003

Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?

artículo científico publicado en 2008

Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia

artículo científico publicado en 2002

Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia

artículo científico publicado en 2003

Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome

artículo científico publicado en 2003

Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase

artículo científico publicado en 2004

Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia

artículo científico

Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast

artículo científico publicado en 2009

Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?

artículo científico publicado en 2011

Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia

artículo científico publicado en 2004

High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia

artículo científico publicado en 2003

Identification of side effects associated with intolerance to BCR-ABL inhibitors in patients with chronic myeloid leukemia.

artículo científico publicado en 2011

Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction

artículo científico publicado en 2010

Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase

artículo científico publicado en 2002

Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy

artículo científico publicado en 2008

Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.

artículo científico publicado en 2002

Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia.

artículo científico publicado en 2002

Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data

artículo científico publicado en 2003

Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses

artículo científico publicado en 2002

Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia

artículo científico publicado en 2004

Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia

artículo científico publicado en 2004

Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience

artículo científico publicado en 2012

Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

artículo científico publicado en 2012

Interleukin 11 May improve thrombocytopenia associated with imatinib mesylate therapy in chronic Myelogenous leukemia

artículo científico publicado en 2004

Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha

artículo científico publicado en 2004

Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies

artículo científico publicado en 2011

Management of molecular-targeted therapy for chronic myelogenous leukemia

artículo científico publicado en 2003

Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challenges.

artículo científico publicado en 2007

Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate

artículo científico publicado en 2005

Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience

artículo científico publicado en 2013

Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias.

artículo científico publicado en 2003

Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.

artículo científico publicado en 2003

Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome

artículo científico publicado en 2012

Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase

artículo científico publicado en 2017

Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia

artículo científico publicado en 2003

Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure

artículo científico publicado en 2010

Pregnancy among patients with chronic myeloid leukemia treated with imatinib

artículo científico publicado en 2006

Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy

artículo científico publicado en 2003

Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia.

artículo científico publicado en 2003

Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha

artículo científico publicado en 2003

Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia

artículo científico publicado en 2003

Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome

artículo científico publicado en 2004

Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders

artículo científico publicado en 2003

Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase

artículo científico publicado en 2003

Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response

artículo científico publicado en 2009

Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy

artículo científico publicado en 2005

Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal

artículo científico publicado en 2006

Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate

artículo científico publicado en 2005

Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implications

artículo científico publicado en 2003

Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls

artículo científico publicado en 2004

Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience

artículo científico publicado en 2005

The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors

artículo científico publicado en 2011

The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy

artículo científico publicado en 2005

The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase

artículo científico publicado en 2004

Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside

artículo científico publicado en 2003

Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.

artículo científico publicado en 2002

Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience

scholarly article by Kamal Chamoun et al published 3 January 2019 in Journal of Hematology & Oncology

Lista de obras de

A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia

Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase

Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations

Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase.

Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase

Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapy

Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance

Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment

Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis

Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?

Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia

Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia

Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome

Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase

Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia

Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast

Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?

Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia

High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia

Identification of side effects associated with intolerance to BCR-ABL inhibitors in patients with chronic myeloid leukemia.

Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction

Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase

Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy

Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.

Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia.

Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data

Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses

Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia

Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia

Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience

Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

Interleukin 11 May improve thrombocytopenia associated with imatinib mesylate therapy in chronic Myelogenous leukemia

Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha

Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies

Management of molecular-targeted therapy for chronic myelogenous leukemia

Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challenges.

Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate

Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience

Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias.

Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.

Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome

Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase

Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia

Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure

Pregnancy among patients with chronic myeloid leukemia treated with imatinib

Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy

Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia.

Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha

Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia

Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome

Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders

Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase

Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response

Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy

Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal

Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate

Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implications

Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls

Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience

The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors

The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy

The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase

Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside

Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.

Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience